Rosa Parisi1, Roger T Webb2, Matthew J Carr2, Kieran J Moriarty3, C Elise Kleyn4, Christopher E M Griffiths4,5, Darren M Ashcroft1,5,6. 1. Centre for Pharmacoepidemiology and Drug Safety, School of Health Sciences, University of Manchester, Manchester Academic Health Science Centre, Manchester, England. 2. Centre for Mental Health and Safety, School of Health Sciences, University of Manchester, Manchester Academic Health Science Centre, Manchester, England. 3. Bolton NHS Foundation Trust, Bolton, England. 4. Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, England. 5. NIHR Manchester Biomedical Research Centre, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, England. 6. NIHR Greater Manchester Patient Safety Translational Research Centre, University of Manchester, Manchester Academic Health Science Centre, Manchester, England.
Abstract
Importance: People diagnosed with psoriasis have an increased risk of premature mortality, but the underlying reasons for this mortality gap are unclear. Objective: To investigate whether patients with psoriasis have an elevated risk of alcohol-related mortality. Design, Setting, and Participants: An incident cohort of patients with psoriasis aged 18 years and older was delineated for 1998 through 2014 using the Clinical Practice Research Datalink (CPRD) and linked to Hospital Episode Statistics (HES) and Office for National Statistics (ONS) mortality records. Patients with psoriasis were matched with up to 20 comparison patients without psoriasis on age, sex, and general practice. Main Outcomes and Measures: Alcohol-related deaths were ascertained via the Office for National Statistics mortality records. A stratified Cox proportional hazard model was used to estimate the cause-specific hazard ratio for alcohol-related death, with adjustment for socioeconomic status. Results: The cohort included 55 537 with psoriasis and 854 314 patients without psoriasis. Median (interquartile) age at index date was 47 (27) years; 408 230 of total patients (44.9%) were men. During a median (IQR) of 4.4 (6.2) years of follow-up, the alcohol-related mortality rate was 4.8 per 10 000 person-years (95% CI, 4.1-5.6; n = 152) for the psoriasis cohort, vs 2.5 per 10 000 (95% CI, 2.4- 2.7; n = 1118) for the comparison cohort. The hazard ratio for alcohol-related death in patients with psoriasis was 1.58 (95% CI, 1.31-1.91), and the predominant causes of alcohol-related deaths were alcoholic liver disease (65.1%), fibrosis and cirrhosis of the liver (23.7%), and mental and behavioral disorders due to alcohol (7.9%). Conclusions and Relevance: People with psoriasis have approximately a 60% greater risk of dying due to alcohol-related causes compared with peers of the same age and sex in the general population. This appears to be a key contributor to the premature mortality gap. These findings call for routine screening, identification and treatment, using the Alcohol Use Disorders Identification Test (AUDIT-C) in both primary and secondary care to detect alcohol consumption and misuse among people diagnosed with psoriasis.
Importance: People diagnosed with psoriasis have an increased risk of premature mortality, but the underlying reasons for this mortality gap are unclear. Objective: To investigate whether patients with psoriasis have an elevated risk of alcohol-related mortality. Design, Setting, and Participants: An incident cohort of patients with psoriasis aged 18 years and older was delineated for 1998 through 2014 using the Clinical Practice Research Datalink (CPRD) and linked to Hospital Episode Statistics (HES) and Office for National Statistics (ONS) mortality records. Patients with psoriasis were matched with up to 20 comparison patients without psoriasis on age, sex, and general practice. Main Outcomes and Measures: Alcohol-related deaths were ascertained via the Office for National Statistics mortality records. A stratified Cox proportional hazard model was used to estimate the cause-specific hazard ratio for alcohol-related death, with adjustment for socioeconomic status. Results: The cohort included 55 537 with psoriasis and 854 314 patients without psoriasis. Median (interquartile) age at index date was 47 (27) years; 408 230 of total patients (44.9%) were men. During a median (IQR) of 4.4 (6.2) years of follow-up, the alcohol-related mortality rate was 4.8 per 10 000 person-years (95% CI, 4.1-5.6; n = 152) for the psoriasis cohort, vs 2.5 per 10 000 (95% CI, 2.4- 2.7; n = 1118) for the comparison cohort. The hazard ratio for alcohol-related death in patients with psoriasis was 1.58 (95% CI, 1.31-1.91), and the predominant causes of alcohol-related deaths were alcoholic liver disease (65.1%), fibrosis and cirrhosis of the liver (23.7%), and mental and behavioral disorders due to alcohol (7.9%). Conclusions and Relevance: People with psoriasis have approximately a 60% greater risk of dying due to alcohol-related causes compared with peers of the same age and sex in the general population. This appears to be a key contributor to the premature mortality gap. These findings call for routine screening, identification and treatment, using the Alcohol Use Disorders Identification Test (AUDIT-C) in both primary and secondary care to detect alcohol consumption and misuse among people diagnosed with psoriasis.
Authors: M A McAleer; D L Mason; S Cunningham; S J O'Shea; P A McCormick; C Stone; P Collins; S Rogers; B Kirby Journal: Br J Dermatol Date: 2011-06 Impact factor: 9.302
Authors: Howa Yeung; Junko Takeshita; Nehal N Mehta; Stephen E Kimmel; Alexis Ogdie; David J Margolis; Daniel B Shin; Rosemary Attor; Andrea B Troxel; Joel M Gelfand Journal: JAMA Dermatol Date: 2013-10 Impact factor: 10.282
Authors: K Al-Jefri; D Newbury-Birch; C R Muirhead; E Gilvarry; V Araújo-Soares; N J Reynolds; E Kaner; P J Hampton Journal: Br J Dermatol Date: 2017-07-07 Impact factor: 9.302
Authors: David A Springate; Evangelos Kontopantelis; Darren M Ashcroft; Ivan Olier; Rosa Parisi; Edmore Chamapiwa; David Reeves Journal: PLoS One Date: 2014-06-18 Impact factor: 3.240
Authors: Alex M Trafford; Rosa Parisi; Martin K Rutter; Evangelos Kontopantelis; Christopher E M Griffiths; Darren M Ashcroft Journal: PLoS One Date: 2021-07-19 Impact factor: 3.240
Authors: Arlene M Gallagher; Daniel Dedman; Shivani Padmanabhan; Hubert G M Leufkens; Frank de Vries Journal: Pharmacoepidemiol Drug Saf Date: 2019-03-25 Impact factor: 2.890
Authors: Hayley C Gorton; Roger T Webb; Rosa Parisi; Matthew J Carr; Marcos DelPozo-Banos; Kieran J Moriarty; W Owen Pickrell; Ann John; Darren M Ashcroft Journal: Front Neurol Date: 2021-01-21 Impact factor: 4.003